Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. - Wikidata - awgldk - TriplyDB

Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer.

Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer.

http://www.wikidata.org/entity/Q37846228

about

Molecular-targeted therapy for advanced gastric cancer Molecular-targeted first-line therapy for advanced gastric cancer TEM7 (PLXDC1), a key prognostic predictor for resectable gastric cancer, promotes cancer cell migration and invasion.Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models.Beclin-1 expression is a significant predictor of survival in patients with lymph node-positive gastric cancer.Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population.Lin28A activates androgen receptor via regulation of c-myc and promotes malignancy of ER-/Her2+ breast cancer.Lin28A and androgen receptor expression in ER-/Her2+ breast cancer.Lin28 regulates HER2 and promotes malignancy through multiple mechanisms.HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma.Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology?Upregulation of bone morphogenetic protein 1 is associated with poor prognosis of late-stage gastric Cancer patients.

P2860

Q24187006-88CD980C-9520-4CDA-8EC6-EE81BB81FD21 Q26471049-61285EBA-BE83-465A-B33D-A93FC7DD8D72 Q35402268-005D18C9-0C70-40EE-A124-D02BBAF55562 Q35998729-2375EF33-54C7-4C8D-B0ED-D1F92B809FC4 Q36284657-3F6C2AE2-F3EA-436B-84F6-AD57D880059F Q36770491-788DB457-87DA-4806-817F-FC825AF5645C Q36897947-59683A02-A0ED-4E4A-A805-D5CF021CEED0 Q37645034-5EB16A91-0CFB-4C2E-9651-9A7E0C23262F Q38788785-B1B6064B-499A-4D68-8B62-C781070E687F Q39328419-420750D4-8043-4BDF-B243-C15A3286B53C Q41839228-A3678809-CD71-413B-B81E-B65A7A28F3F0 Q42558684-25A25669-8D68-499D-AF9F-756D9C540806 Q55154175-8C0E6D9F-E63E-45D5-BFEC-E336411D7BA6

P2860

Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer.

http://www.wikidata.org/entity/Q37846228

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Trastuzumab: a new treatment o ...... troesophageal junction cancer.

@en

Trastuzumab: a new treatment o ...... troesophageal junction cancer.

@nl

type

label

Trastuzumab: a new treatment o ...... troesophageal junction cancer.

@en

Trastuzumab: a new treatment o ...... troesophageal junction cancer.

@nl

prefLabel

Trastuzumab: a new treatment o ...... troesophageal junction cancer.

@en

Trastuzumab: a new treatment o ...... troesophageal junction cancer.

@nl

P1433

Q37846228-E145FD91-DAEC-4B7B-B7EC-2CFA7084A867

P1476

Q37846228-3EDB7F55-2142-46C5-A21C-964455D5A9E8

P2093

Q37846228-F58BC5FB-7494-423B-8F08-A4EB5BE752D2

P2860

Q37846228-0430B5C8-004B-4501-AE8F-9C98668CA92B

Q37846228-04FFB655-B431-4213-83E7-E6F2FC9EE10F

Q37846228-07874158-2136-4D49-8E7B-0C6BFE32B18B

Q37846228-0920758B-285F-4BB0-98E2-07D7EFC1CBD9

Q37846228-12BE3BBD-B9B8-44C4-88BD-5573C5CD2BB3

Q37846228-13C53F9C-B28B-4BFB-A90C-36A13B561E22

Q37846228-1E231D77-421D-4C76-B27B-B85E470A8225

Q37846228-23FB129C-CC29-4440-AAC4-8A5DF458D931

Q37846228-2478833C-91E1-49DD-AC24-E0F0FF7C1409

Q37846228-2544B66C-AB15-459B-BB5D-59EDA40CD8A5

P304

Q37846228-5D0454FE-48A4-40C1-ADDF-0CB1903A47F1

P31

Q37846228-46ECF648-73BC-44AB-BE5C-D5E277EAC26C

P356

Q37846228-15F7D165-7B76-420A-B367-1004C4E45CA2

P407

Q37846228-79CC4150-0E11-4A00-9F9D-9A534C0DE824

P433

Q37846228-54C42AA6-0321-412F-922C-D2E4C4E12A94

P478

Q37846228-4F4CC988-9C36-4764-AF4C-0399FCABA134

P577

Q37846228-BA823318-458F-4E8F-A4E6-14FD269E8706

P698

Q37846228-A08DA6A8-D4A4-47F9-BD8A-59218A6876C2

P356

P1433

Future Oncology

P1476

Trastuzumab: a new treatment o ...... troesophageal junction cancer.

@en

P2093

Florian Lordick

http://www.w3.org/2001/XMLSchema#string

P2860

Humanization of an anti-p185HER2 antibody for human cancer therapy

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Untangling the ErbB signalling network

P304

187-199

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.10.178

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21345138

http://www.w3.org/2001/XMLSchema#string